Lantern Pharma Inc.

LTRN Nasdaq SEC CIK 1763950
Follow Lantern Pharma Weekly email: filings, results

Financials

Reported figures only · latest: Q2 2026 USD · US GAAP
Net income −$7.1M −63.3% vs same quarter last year
EPS, diluted −$0.57 −42.5% vs same quarter last year
Operating cash flow −$2.9M +25.3% vs same quarter last year
Operating income −$3.5M +24.6% vs same quarter last year
Net income by quarter
−$4.5M
−$5.9M
−$4.5M
−$4.3M
−$4.2M
−$4.1M
−$3.3M
−$7.1M
Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
−$30M−$20M−$10M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$17.1M
FY24−$20.8M
FY23−$16M
FY22−$14.3M
FY21−$12.4M
FY20−$5.9M
FY19−$2.4M
FY18-
Free cash flowOperating cash flow minus capital expenditure
−$20M−$15M−$10M−$5M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$15.7M
FY24−$17.8M
FY23−$14.4M
FY22−$12.8M
FY21−$10.6M
FY20-
FY19-
FY18-
Returned to shareholdersDividends paid and shares bought back
$0$1M$2M$3MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearBuybacks
FY25-
FY24-
FY23$500K
FY22$2.5M
FY21$939.7K
FY20-
FY19-
FY18-